Key Highlights

● TNL Mediagene ( Nasdaq :TNMG) received a formal delisting determination from Nasdaq on June 22, 2026, disclosed in a Form 6-K filed June 26, after falling below compliance thresholds.

● Because TNL Mediagene had executed a Reverse Stock Split within the previous year, it was ineligible for the automatic cure period usually granted to companies slipping below the bid-price requirement.

● For the year ended December 31, 2025, TNL Mediagene reported Revenue of $45.0 million, with its digital studio segment the largest at $18.7 million, or 41.4% of revenue.

● The going-concern warning and year-end cash under $2 million loom large, with a Nasdaq Hearings Panel decision the most immediate signpost investors should watch.

A delisting notice sharpens the deadline

On 22 June 2026, TNL Mediagene received a formal delisting determination from Nasdaq, disclosed in a Form 6-K filed with the US Securities and Exchange Commission on 26 June. The exchange cited two breaches: the shares had closed below the US$1.00 minimum bid price for 30 consecutive trading days (7 May-18 June 2026), contravening Rule 5550(a)(2), and the group had failed to maintain the US$2,500,000 minimum stockholders' Equity required under Rule 5550(b)(1).

Critically, because TNL Mediagene had executed a reverse stock split within the previous year, it was ineligible for the automatic cure period usually granted to companies that slip below the bid-price threshold. It said it intended to request a hearing before a Nasdaq Hearings Panel, a step that automatically stays any suspension of its securities pending the decision. The shares keep trading under TNMG in the meantime, though the company cautioned there is no assurance the panel will grant continued listing.

From de-SPAC to Asian media group

TNL Mediagene was created by the 2023 Merger of Taiwan's The News Lens and Japan's Mediagene, and it completed a Business combination with special-purpose Acquisition company Blue Ocean Acquisition Corp to list on the Nasdaq Capital Market on 6 December 2024. That de-SPAC route, in which a private company merges with a listed cash shell rather than pursuing a traditional initial public offering, delivered a listing but, as later filings showed, left the group thinly capitalised.

Headquartered across Tokyo and Taipei with offices in Kyoto and Hong Kong, the company calls itself one of the first Asian digital-media groups on Nasdaq. It publishes roughly 22 media brands, including Business Insider Japan, Gizmodo Japan, The News Lens and Roomie, which it says reach upwards of 40 million monthly unique users. Alongside ad-supported publishing, it runs a digital studio, a branded-content arm and a technology unit with proprietary Advertising networks and data products.

Losses narrow, but cash runs thin

For the year ended 31 December 2025, TNL Mediagene reported revenue of US$45.0 million, per the results release accompanying its Form 20-F filed on 12 May 2026. That missed the roughly US$49.1 million earlier guided, blamed on softer-than-expected digital-studio and media performance. The net loss narrowed sharply to US$44.6 million from US$85.0 million a year earlier, an improvement of about US$40.4 million, mostly from the absence of a US$38.2 million one-time, non-cash listing charge booked in 2024 and lower finance costs.

The digital studio was the largest segment at US$18.7 million, or 41.4 per cent of revenue. Crucially, the audited statements carried a going-concern emphasis-of-matter paragraph, and the company held just US$1.9 million in cash at year-end, needing additional financing to fund operations beyond FY2026. In the first half of 2025, revenue rose 5.7 per cent to US$21.8 million and the net loss narrowed to US$4.3 million, with adjusted EBITDA a negative US$3.2 million.

The AI advertising bet

Management's turnaround thesis rests heavily on technology and artificial intelligence. In February 2026 the company set a target of EBITDA break-even in fiscal 2026 and positive EBITDA in 2027, via growth in technology-business revenue, organisational restructuring and automation-driven cost cuts. EBITDA, Earnings before interest, tax, Depreciation and Amortisation , is a non-GAAP measure that excludes several costs, so break-even on that basis is not a bottom-line accounting profit.

Chief executive and co-founder Joey Chung said the group was "focused on building a more efficient and scalable organization" and aiming for those targets "through organic growth of our core businesses, new product development, and disciplined strategic acquisitions." The centrepiece is advertising-technology Subsidiary Ad2iction, whose Ad2 AI Audience platform integrates retail transaction and intent signals, and its Ad2 AI Agent service, described as AI advertising built on smart-audience and smart-creative automation. Technology revenue reached US$6.0 million in the first half of 2025, aided by consolidating the Dragon acquisition completed in September 2024.

A demanding competitive backdrop

The industry backdrop is unforgiving. Digital publishers across Asia are contending with advertising budgets migrating toward a handful of dominant platforms, volatile programmatic-ad pricing and generative AI's disruption of search-driven referral traffic. TNL Mediagene positions its first-party data and AI advertising tools as a differentiator in Japan and Taiwan, arguing that local-language scale and audience data are harder for global platforms to replicate. Yet it competes with far larger, better-capitalised rivals. Whether AI ad products can grow fast enough to offset structural pressure on legacy media revenue is the central operational question.

Balance-sheet and listing risks loom large

The risks are substantial and interlinked. The going-concern warning and year-end cash under US$2 million underscore an acute need for capital, and any equity raise at the depressed share price, around US$0.36 in early August 2026, for a Market Capitalisation below US$1 million, would be heavily dilutive. The 1-for-20 reverse stock split completed in December 2025 lifted the price only temporarily, did not resolve the equity shortfall, and cost the company its standard bid-price cure period.

Failure at the Nasdaq hearing would likely push the shares to the over-the-counter market, typically reducing Liquidity and institutional ownership. As a foreign private issuer, the group reports semi-annually rather than quarterly and under IFRS, giving less frequent visibility, while yen, New Taiwan dollar and US dollar swings add Volatility to results.

What investors should watch next

Several near-term signposts will shape the outcome. Foremost is the Nasdaq Hearings Panel decision, which will determine whether TNMG keeps its listing and on what conditions; the company had already been under a one-year panel monitor after regaining bid-price compliance in January 2026. Investors will also watch for any financing that addresses the going-concern and minimum-equity gaps, progress toward the FY2026 EBITDA break-even target, the trajectory of AI advertising revenue, and first-half 2026 results due later this year. Evidence that cost cuts are landing without eroding the media Franchise would bolster the case.

A speculative situation against the clock

TNL Mediagene presents a stark risk-reward proposition. On one side sits a genuine operating story: a sizeable Asian audience, recognisable brands, a narrowing net loss and an AI strategy aimed at a profitability milestone. On the other sits a Balance Sheet stretched to breaking point, a going-concern flag and a delisting determination resolved by a Nasdaq panel, not management. The company's targets sketch a path to EBITDA break-even, but reaching it demands both execution and fresh funding on terms that do not overwhelm shareholders. For now, the listing clock and the financing question loom at least as large as the technology thesis.

This article is general information only and does not constitute personal financial advice, an offer, a solicitation or a recommendation to buy or sell any security. Investors should conduct their own research and consider obtaining professional advice before making Investment decisions.